コンテンツへスキップ
Merck
  • Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

ACS nano (2015-02-18)
Jin Han, Bokyoung Kim, Jung-Youn Shin, Seungmi Ryu, Myungkyung Noh, Jongsu Woo, Jin-Sil Park, Youjin Lee, Nohyun Lee, Taeghwan Hyeon, Donghoon Choi, Byung-Soo Kim
要旨

Electrophysiological phenotype development and paracrine action of mesenchymal stem cells (MSCs) are the critical factors that determine the therapeutic efficacy of MSCs for myocardial infarction (MI). In such respect, coculture of MSCs with cardiac cells has windowed a platform for cardiac priming of MSCs. Particularly, active gap junctional crosstalk of MSCs with cardiac cells in coculture has been known to play a major role in the MSC modification through coculture. Here, we report that iron oxide nanoparticles (IONPs) significantly augment the expression of connexin 43 (Cx43), a gap junction protein, of cardiomyoblasts (H9C2), which would be critical for gap junctional communication with MSCs in coculture for the generation of therapeutic potential-improved MSCs. MSCs cocultured with IONP-harboring H9C2 (cocultured MSCs: cMSCs) showed active cellular crosstalk with H9C2 and displayed significantly higher levels of electrophysiological cardiac biomarkers and a cardiac repair-favorable paracrine profile, both of which are responsible for MI repair. Accordingly, significantly improved animal survival and heart function were observed upon cMSC injection into rat MI models compared with the injection of unmodified MSCs. The present study highlights an application of IONPs in developing gap junctional crosstalk among the cells and generating cMSCs that exceeds the reparative potentials of conventional MSCs. On the basis of our finding, the potential application of IONPs can be extended in cell biology and stem cell-based therapies.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
オレイン酸, technical grade, 90%
Sigma-Aldrich
塩化チタン(IV), ReagentPlus®, 99.9% trace metals basis
Sigma-Aldrich
ローダミンB, ≥95% (HPLC)
Sigma-Aldrich
オレイン酸, BioReagent, suitable for cell culture
Sigma-Aldrich
塩化チタン(IV) 溶液, 1.0 M in methylene chloride
Sigma-Aldrich
L-リシン 一塩酸塩, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
ベンジルエーテル, 98%
Sigma-Aldrich
ローダミンB, for fluorescence
Sigma-Aldrich
オレイン酸, ≥99% (GC)
Sigma-Aldrich
オレイン酸, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Sigma-Aldrich
オレイン酸, natural, FCC
Sigma-Aldrich
塩化チタン(IV), ≥99.995% trace metals basis
Sigma-Aldrich
カルセイン AM, suitable for fluorescence, BioReagent, ≥95.0% (HPLC)
Sigma-Aldrich
塩化チタン(IV) 溶液, 0.09 M in 20% HCl
Sigma-Aldrich
L-リシン 一塩酸塩, reagent grade, ≥98% (HPLC)
Supelco
オレイン酸, analytical standard
Sigma-Aldrich
カルセイン AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Sigma-Aldrich
四塩化チタン, packaged for use in deposition systems
Sigma-Aldrich
ジベンジルエーテル, purum, ≥98.0% (GC)
Supelco
ローダミンB, analytical standard
Sigma-Aldrich
カルセイン AM 溶液, 4 mM in DMSO, ≥90% (HPLC), solution
Supelco
L-リシン 一塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
ベンジルエーテル, ≥98%, FCC, FG
Sigma-Aldrich
L-リシン 一塩酸塩, BioUltra, ≥99.5% (AT)
リシン 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
オレイン酸, Selectophore, ≥99%
Supelco
L-リシン 一塩酸塩, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
ローダミンB 溶液, 0.2% in isopropanol, for TLC derivatization
Sigma-Aldrich
オレイン酸, SAJ first grade, ≥70.0%